Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies helping to avoid unnecessary hysterectomies and improve and save lives.
Gynion is developing a therapeutic platform for multiple indications in gynecology and dermatology.
ClarablexTM is a topical gel for deep tissue ablation. It is a treatment for multiple indications in gynecology and dermatology, including cervical intraepithelial neoplasia (CIN) caused by human papillomavirus (HPV) to prevent cervical cancer. In the pre-clinical trial, Clarablex demonstrates results that are expected to be sufficient to treat CIN2+.
MenorrxTM is a therapy for Heavy Menstrual Bleeding (HMB). In the pre-clinical trial, Menorrx shows promise to be a safe and effective non-invasive in-office treatment. It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.
Founder & CEO
Victoria Shikhman, ND
Founder & interim VP of Clinical Research
Doctor of Naturopathic Medicine
Steven Goldstein, MD
Professor of OBGYN at NYU Medical Center
Business Development Advisor
Malcolm Munro, MD
Professor of OBGYN, UCLA
FIGO Menstrual Disorders Committee
Amy Garcia, MD
Medical Director, The Center for Women’s Surgery
Paul Blumenthal, MD
Professor of OBGYN,
Tulay Okman Kilic, MD
Professor of OBGYN
Juan Canela Oleaga, MD
Director of OBGYN Surgery
Oleg Shikhman, CEO